×
CSL Cash on Hand 2017-2024 | CSLLY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CSL cash on hand for the quarter ending June 30, 2024 was
$1.657B
, a
73.85% decline
year-over-year.
CSL cash on hand for 2024 was
$1.657B
, a
7.04% increase
from 2023.
CSL cash on hand for 2023 was
$1.548B
, a
85.17% decline
from 2022.
CSL cash on hand for 2022 was
$10.441B
, a
475.71% increase
from 2021.
View More
CSL Cash on Hand 2017-2024 | CSLLY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CSL cash on hand for 2024 was
$1.657B
, a
7.04% increase
from 2023.
CSL cash on hand for 2023 was
$1.548B
, a
85.17% decline
from 2022.
CSL cash on hand for 2022 was
$10.441B
, a
475.71% increase
from 2021.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$173B
Vertex Pharmaceuticals (VRTX)
$127.1B
Gilead Sciences (GILD)
$114.2B
Bristol Myers Squibb (BMY)
$112.1B
Regeneron Pharmaceuticals (REGN)
$89.7B
GSK (GSK)
$74.4B
Argenex SE (ARGX)
$35.2B
Alnylam Pharmaceuticals (ALNY)
$35.2B
Biogen (BIIB)
$25.4B
BioNTech SE (BNTX)
$25.4B
Illumina (ILMN)
$24.2B
Moderna (MRNA)
$19.9B
BeiGene (BGNE)
$19.7B
Incyte (INCY)
$15.6B
Genmab (GMAB)
$14.8B
Insmed (INSM)
$13B
Vaxcyte (PCVX)
$13B
BioMarin Pharmaceutical (BMRN)
$12.6B
Sarepta Therapeutics (SRPT)
$12.2B
Bio-Techne Corp (TECH)
$12B
Exelixis (EXEL)
$10.1B
Exact Sciences (EXAS)
$10.1B
QIAGEN (QGEN)
$10B
Revolution Medicines (RVMD)
$9.9B
Intra-Cellular Therapies (ITCI)
$9.5B
Bio-Rad Laboratories (BIO.B)
$9.4B
Roivant Sciences (ROIV)
$8.7B
Repligen (RGEN)
$8.2B
Ascendis Pharma (ASND)
$7.8B
Halozyme Therapeutics (HALO)
$7.7B